Pre-market hot trades in US stocks: Evoke Pharma pre-market down 7.89%

Tracking Unusual Activity
2025.07.21 12:27
portai
I'm PortAI, I can summarize articles.

Evoke Pharma pre-market down 7.89%; GlucoTrack pre-market up 73.06%; Helius Medical Tech pre-market up 70.67%; reAlpha Tech pre-market up 39.21%

Popular Pre-Market Trades in U.S. Stocks

Evoke Pharma is down 7.89% in pre-market trading. Based on recent important news:

  1. On July 9, Evoke Pharma released information through EDGAR, leading to increased stock price volatility.

  2. On July 10, Evoke Pharma obtained a new patent for GIMOTI, causing the stock price to rise.

  3. Recently, the U.S. pharmaceutical industry is facing policy uncertainties, affecting stock prices.

Top Gainers in Pre-Market Trading in U.S. Stocks

GlucoTrack is up 73.06% in pre-market trading. Based on recent key news:

  1. On June 25, GlucoTrack announced that its new non-invasive blood glucose monitoring device received FDA approval, resulting in a positive market reaction and a significant stock price increase.

  2. On June 26, GlucoTrack signed a strategic cooperation agreement with a large medical device company, further boosting market confidence and driving the stock price up.

  3. On June 27, a well-known analyst raised GlucoTrack's target price, expecting a significant increase in its market share, leading to a corresponding rise in stock price.

Helius Medical Tech is up 70.67% in pre-market trading. Based on recent important news:

  1. On July 21, Helius announced positive results from its portable neurostimulation device PONS® stroke registration program and plans to submit a breakthrough designation application to the FDA in the third quarter of 2025, significantly boosting the stock price.

  2. On July 21, Helius confirmed that studies on PONS treatment showed very few adverse events, enhancing market confidence.

  3. On July 21, news of Helius's plans to submit an FDA application further stimulated investor optimism.

reAlpha Tech is up 39.21% in pre-market trading. Based on recent key news:

  1. On May 16, reAlpha Tech announced a 4432% year-over-year revenue growth for the quarter ending March 31, leading to a surge in stock price.

  2. On July 16, reAlpha Tech announced a $2 million public offering, causing the stock price to drop by 25.7%.

  3. On July 17, reAlpha Tech's public offering was priced at $0.15 per share, and the stock price continued to decline

Source: Tracking Unusual Activity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.